Fusobacterium nucleatum: from a classic periodontal pathogen to a complete participant of carcinogenesis

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):13-18

​ Kaiumov K.A., Lyamin A.V., Zhestkov A.V., Bazhutova I.V.
10.36488/cmac.2023.1.13-18
Fusobacterium nucleatum colorectal cancer carcinogenesis
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):13-18

Abstract

Fusobacterium nucleatum is a component of the oral microflora, and in clinical practice it is associated primarily with periodontal diseases. Since 2011, the scientific community has confirmed the association of F. nucleatum with colorectal cancer (CRC) by seeding it from tumor tissue samples. Research has led to the discovery of mechanisms by which this bacterium may contribute to the development, metastasis of CRC and chemoresistance. With the help of its adhesion proteins (FadA and Fap2) F. nucleatum specifically attaches to colorectal carcinoma cells. Following invasion, F. nucleatum induces inflammation, activates β-catenin signaling, and creates a favorable microenvironment for tumor growth and development. Recently, the role of F. nucleatum in other types of oncological pathology, such as oral cavity cancer, head and neck cancer, gastric cancer, esophageal cancer, pancreatic cancer, cervical cancer and breast cancer, has been confirmed. Understanding the mechanisms of association of F. nucleatum with oncological diseases will help to find new approaches in the treatment, prevention and diagnosis of cancer. Thus, further studies of the correlation between F. nucleatum and carcinogenesis are needed, using a multidisciplinary approach and physicians from other specialties.

Karim A. Kaiumov

Samara State Medical University, Samara, Russia

Artem V. Lyamin

Samara State Medical University, Samara, Russia

Zhestkov A.V.

Samara State Medical University, Samara, Russia

Bazhutova I.V.

Samara State Medical University, Samara, Russia

  • 1. Tierra Rodríguez A.M., Raya Fernández C. Septic shock caused by Leptotrichia buccalis in a neutropenic patient secondary to chemotherapy. Enferm Infecc Microbiol Clin (Engl Ed). 2020;38(1):41-42. DOI: 10.1016/j.eimc.2019.01.008
  • 2. Bhally H.S., Lema C., Romagnoli M., Borek A., Wakefield T., Carroll K.C. Leptotrichia buccalis bacteremia in two patients with acute myelogenous leukemia. Anaerobe. 2005;11(6):350-353. DOI: 10.1016/j.anaerobe.2005.04.001
  • 3. Weinberger M., Wu T., Rubin M., Gill V.J., Pizzo P.A. Leptotrichia buccalis bacteremia in patients with cancer: report of four cases and review. Rev Infect Dis. 1991;13(2):201-206. DOI: 10.1093/clinids/13.2.201
  • 4. Theis K.R., Florova V., Romero R., Borisov A.B., Winters A.D., Galaz J., et al. Sneathia: an emerging pathogen in female reproductive disease and adverse perinatal outcomes. Crit Rev Microbiol. 2021;47(4):517-542. DOI: 10.1080/1040841X.2021.1905606
  • 5. Gruwier L., Sprenkels A., Hulsbosch S., Vankeerberghen A., Cartuyvels R. Sneathia amnii bacteraemia and chorioamnionitis leading to second trimester abortion: a case report. Access Microbiol. 2021;3(12):000290. DOI: 10.1099/acmi.0.000290
  • 6. Vitorino P., Varo R., Castillo P., Hurtado J.C., Fernandes F., Valente A.M., et al. Sneathia amnii and maternal chorioamnionitis and stillbirth, Mozambique. Emerg Infect Dis. 2019;25(8):1614-1616. DOI: 10.3201/eid2508.190526
  • 7. Coppenhagen-Glazer S., Sol A., Abed J., Naor R., Zhang X., Han Y.W., et al. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Infect Immun. 2015;83(3):1104-1113. DOI: 10.1128/IAI.02838-14
  • 8. Chen Y., Huang Z., Tang Z., Huang Y., Huang M., Liu H., et al. More than just a periodontal pathogen – the research progress on Fusobacterium nucleatum. Front Cell Infect Microbiol. 2022;12:815318. DOI: 10.3389/fcimb.2022.815318
  • 9. Stokowa-Sołtys K., Wojtkowiak K., Jagiełło K. Fusobacterium nucleatum – friend or foe? J Inorg Biochem. 2021;224:111586. DOI: 10.1016/j.jinorgbio.2021.111586
  • 10. Signat B., Roques C., Poulet P., Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol. 2011;13(2):25-36. PMID: 21220789.
  • 11. Allen-Vercoe E., Strauss J., Chadee K. Fusobacterium nucleatum: an emerging gut pathogen? Gut Microbes. 2011;2(5):294-298. DOI: 10.4161/gmic.2.5.18603
  • 12. Curtis M.A., Aduse-Opoku J., Rangarajan M. Cysteine proteases of Porphyromonas gingivalis. Crit Rev Oral Biol Med. 2001;12(3):192-216. DOI: 10.1177/10454411010120030101
  • 13. Brennan C.A., Garrett W.S. Fusobacterium nucleatum – symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156-166. DOI: 10.1038/s41579-0180129-6
  • 14. Wong S.H., Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690-704. DOI: 10.1038/s41575-019-0209-8
  • 15. Han Y.W., Fardini Y., Chen C., Iacampo K.G., Peraino V.A., Shamonki J.M., et al. Term stillbirth caused by oral Fusobacterium nucleatum. Obstet Gynecol. 2010;115(2 Pt 2):442-445. DOI: 10.1097/AOG.0b013e3181cb9955
  • 16. Han Y.W. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol. 2015;23:141-147. DOI: 10.1016/j.mib.2014.11.013
  • 17. Vander Haar E.L., So J., Gyamfi-Bannerman C., Han Y.W. Fusobacterium nucleatum and adverse pregnancy outcomes: epidemiological and mechanistic evidence. Anaerobe. 2018;50:55-59. DOI: 10.1016/j.anaerobe.2018.01.008
  • 18. Piekut T., Hurła M., Banaszek N., Szejn P., Dorszewska J., Kozubski W., et al. Infectious agents and Alzheimer's disease. J Integr Neurosci. 2022;21(2):73. DOI: 10.31083/j.jin2102073
  • 19. Pyysalo M.J., Pyysalo L.M., Pessi T., Karhunen P.J., Öhman J.E. The connection between ruptured cerebral aneurysms and odontogenic bacteria. J Neurol Neurosurg Psychiatry. 2013;84(11):1214-1218. DOI: 10.1136/jnnp-2012-304635
  • 20. Zhou J., Liu L., Wu P., Zhao L., Wu Y. Fusobacterium nucleatum accelerates atherosclerosis via macrophagedriven aberrant proinflammatory response and lipid metabolism. Front Microbiol. 2022;13:798685. DOI: 10.3389/fmicb.2022.798685
  • 21. Shammas N.W., Murphy G.W., Eichelberger J., Klee D., Schwartz R., Bachman W. Infective endocarditis due to Fusobacterium nucleatum: case report and review of the literature. Clin Cardiol. 1993;16(1):72-75. DOI: 10.1002/clc.4960160116
  • 22. Brook I., de Leyva F. Microbiology of tonsillar surfaces in infectious mononucleosis. Arch Pediatr Adolesc Med. 1994;148(2):171-173. DOI: 10.1001/archpedi.1994.02170020057009
  • 23. Marina M., Strong C.A., Civen R., Molitoris E., Finegold S.M. Bacteriology of anaerobic pleuropulmonary infections: preliminary report. Clin Infect Dis. 1993;16(Suppl. 4):S256-S262. DOI: 10.1093/clinids/16.supplement_4.s256
  • 24. Roberts G.L. Fusobacterial infections: an underestimated threat. Br J Biomed Sci. 2000;57(2):156-162. PMID: 10912293.
  • 25. Global Cancer Observatory. Available at: https://gco.iarc.fr/. Accessed November 2022.
  • 26. Soman R., Eashwernath R. Bacteremia due to Streptococcus gallolyticus: a name with an ominous significance? Indian J Crit Care Med. 2020;24(10):901-902. DOI: 10.5005/jp-journals-10071-23623
  • 27. Thind S.K., Shibib D.R., Gentry C.A. The effect of nomenclature revision of Streptococcus bovis to Streptococcus gallolyticus on subsequent colon cancer screening. Open Forum Infect Dis. 2021;8(9):ofab426. DOI: 10.1093/ofid/ofab426
  • 28. Cheng W.T., Kantilal H.K., Davamani F. The mechanism of Bacteroides fragilis toxin contributes to colon cancer formation. Malays J Med Sci. 2020;27(4):9-21. DOI: 10.21315/mjms2020.27.4.2
  • 29. Haghi F., Goli E., Mirzaei B., Zeighami H. The association between fecal enterotoxigenic B. fragilis with colorectal cancer. BMC Cancer. 2019;19(1):879. DOI: 10.1186/s12885-019-6115-1
  • 30. Ohkusa T., Okayasu I., Ogihara T., Morita K., Ogawa M., Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52(1):79-83. DOI: 10.1136/gut.52.1.79
  • 31. Swidsinski A., Dörffel Y., Loening-Baucke V., Theissig F., Rückert J.C., Ismail M., et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011;60(1):34-40. DOI: 10.1136/gut.2009.191320
  • 32. Strauss J., Kaplan G.G., Beck P.L., Rioux K., Panaccione R., Devinney R., et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17(9):19711978. DOI: 10.1002/ibd.21606
  • 33. Kostic A.D., Gevers D., Pedamallu C.S., Michaud M., Duke F., Earl A.M., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292-298. DOI: 10.1101/gr.126573.111
  • 34. Lee J.B., Kim K.A., Cho H.Y., Kim D., Kim W.K., Yong D., et al. Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Sci Rep. 2021;11(1):20263. DOI: 10.1038/s41598-02198941-6
  • 35. Xu C., Fan L., Lin Y., Shen W., Qi Y., Zhang Y., et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347. DOI: 10.1080/19490976.2021.1980347
  • 36. Chen S., Su T., Zhang Y., Lee A., He J., Ge Q., et al. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut Microbes. 2020;11(3):511-525. DOI: 10.1080/19490976.2019.1695494
  • 37. Chen Y., Chen Y., Zhang J., Cao P., Su W., Deng Y., et al. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics. 2020;10(1):323-339. DOI: 10.7150/thno.38870
  • 38. Yu T., Guo F., Yu Y., Sun T., Ma D., Han J., et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548-563. e16. DOI: 10.1016/j.cell.2017.07.008
  • 39. Ramos A., Hemann M.T. Drugs, bugs, and cancer: Fusobacterium nucleatum promotes chemoresistance in colorectal cancer. Cell. 2017;170(3):411-413. DOI: 10.1016/j.cell.2017.07.018
  • 40. Zhang S., Yang Y., Weng W., Guo B., Cai G., Ma Y., et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):14. DOI: 10.1186/s13046-018-0985-y
  • 41. Abed J., Emgård J.E., Zamir G., Faroja M., Almogy G., Grenov A., et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016; 20(2):215-225. DOI: 10.1016/j.chom.2016.07.006
  • 42. Wang S., Liu Y., Li J., Zhao L., Yan W., Lin B., et al. Fusobacterium nucleatum acts as a pro-carcinogenic bacterium in colorectal cancer: from association to causality. Front Cell Dev Biol. 2021;9:710165. DOI: 10.3389/fcell.2021.710165
  • 43. Shang F.M., Liu H.L. Fusobacterium nucleatum and colorectal cancer: a review. World J Gastrointest Oncol. 2018;10(3):71-81. DOI: 10.4251/wjgo.v10.i3.71
  • 44. Datorre J.G., de Carvalho A.C., Guimarães D.P., Reis R.M. The role of Fusobacterium nucleatum in colorectal carcinogenesis. Pathobiology. 2021;88(2):127-140. DOI: 10.1159/000512175
  • 45. Komiya Y., Shimomura Y., Higurashi T., Sugi Y., Arimoto J., Umezawa S., et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut. 2019;68(7):13351337. DOI: 10.1136/gutjnl-2018-316661
  • 46. Chen S., Zhang L., Li M., Zhang Y., Sun M., Wang L., et al. Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis. Nat Commun. 2022;13(1):1248. DOI: 10.1038/s41467-022-28913-5
  • 47. Meng Q., Gao Q., Mehrazarin S., Tangwanichgapong K., Wang Y., Huang Y., et al. Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity. EMBO Rep. 2021;22(7):e52891. DOI: 10.15252/embr.202152891
  • 48. Rubinstein M.R., Wang X., Liu W., Hao Y., Cai G., Han Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206. DOI: 10.1016/j.chom.2013.07.012
  • 49. Rubinstein M.R., Baik J.E., Lagana S.M., Han R.P., Raab W.J., Sahoo D., et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 2019;20(4):e47638. DOI: 10.15252/embr.201847638
  • 50. Hashemi Goradel N., Heidarzadeh S., Jahangiri S., Farhood B., Mortezaee K., Khanlarkhani N., et al. Fusobacterium nucleatum and colorectal cancer: a mechanistic overview. J Cell Physiol. 2019;234(3):2337-2344. DOI: 10.1002/jcp.27250
  • 51. Li R., Shen J., Xu Y. Fusobacterium nucleatum and colorectal cancer. Infect Drug Resist. 2022;15:1115-1120. DOI: 10.2147/IDR.S357922
  • 52. Kong C., Yan X., Zhu Y., Zhu H., Luo Y., Liu P., et al. Fusobacterium nucleatum promotes the development of colorectal cancer by activating a cytochrome P450/epoxyoctadecenoic acid axis via TLR4/Keap1/NRF2 signaling. Cancer Res. 2021;81(17):4485-4498. DOI: 10.1158/0008-5472.CAN-21-0453
  • 53. Alon-Maimon T., Mandelboim O., Bachrach G. Fusobacterium nucleatum and cancer. Periodontol 2000. 2022;89(1):166-180. DOI: 10.1111/prd.12426
  • 54. He Z., Tian W., Wei Q., Xu J. Involvement of Fusobacterium nucleatum in malignancies except for colorectal cancer: a literature review. Front Immunol. 2022;13:968649. DOI: 10.3389/fimmu.2022.968649
  • 55. Parhi L., Alon-Maimon T., Sol A., Nejman D., Shhadeh A., Fainsod-Levi T., et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259. DOI: 10.1038/s41467-020-16967-2
  • 56. Van der Merwe M., Van Niekerk G., Botha A., Engelbrecht A.M. The onco-immunological implications of Fusobacterium nucleatum in breast cancer. Immunol Lett. 2021;232:60-66. DOI: 10.1016/j.imlet.2021.02.007
  • 57. Huang S.T., Chen J., Lian L.Y., Cai H.H., Zeng H.S., Zheng M., et al. Intratumoral levels and prognostic significance of Fusobacterium nucleatum in cervical carcinoma. Aging (Albany NY). 2020;12(22):2333723350. DOI: 10.18632/aging.104188
  • 58. Li Z., Shi C., Zheng J., Guo Y., Fan T., Zhao H., et al. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma. BMC Microbiol. 2021;21(1):301. DOI: 10.1186/s12866-021-02352-6
  • 59. Yamamura K., Baba Y., Nakagawa S., Mima K., Miyake K., Nakamura K., et al. Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574-5581. DOI: 10.1158/1078-0432.CCR-16-1786
  • 60. Nomoto D., Baba Y., Liu Y., Tsutsuki H., Okadome K., Harada K., et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway. Cancer Lett. 2022;530:59-67. DOI: 10.1016/j.canlet.2022.01.014
  • 61. Șurlin P., Nicolae F.M., Șurlin V.M., Pătrașcu Ș., Ungureanu B.S., Didilescu A.C., et al. Could periodontal disease through periopathogen Fusobacterium nucleatum be an aggravating factor for gastric cancer? J Clin Med. 2020;9(12):3885. DOI: 10.3390/jcm9123885
  • 62. Hsieh Y.Y., Tung S.Y., Pan H.Y., Chang T.S., Wei K.L., Chen W.M., et al. Fusobacterium nucleatum colonization is associated with decreased survival of Helicobacter pylori-positive gastric cancer patients. World J Gastroenterol. 2021;27(42):7311-7323. DOI: 10.3748/wjg.v27.i42.7311
  • 63. Boehm E.T., Thon C., Kupcinskas J., Steponaitiene R., Skieceviciene J., Canbay A., et al. Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients. Sci Rep. 2020;10(1):16240. DOI: 10.1038/s41598-020-73448-8
  • 64. Udayasuryan B., Ahmad R.N., Nguyen T.T.D., Umaña A., Monét Roberts L., Sobol P., et al. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling. Sci Signal. 2022;15(756):eabn4948. DOI: 10.1126/scisignal.abn4948
  • 65. Bučević Popović V., Šitum M., Chow CT., Chan LS., Roje B., Terzić J. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8(1):12157. DOI: 10.1038/s41598-018-29054-w
Views
0 Abstract
0 PDF
0 Crossref citations
Shared